https://www.selleckchem.com/pr....oducts/SB-203580.htm
Two measures pertained to patient education and five to diagnosis, including discussing treatment options with risk and benefits and using the most recent version of the Chicago Classification to define achalasia phenotypes, respectively. Other indicators pertained to treatment options, such as the use of botulinum toxin for those not considered surgical candidates and management of reflux following achalasia treatment. Using a robust methodology, achalasia quality indicators were identified, which can form the basis for establishing